ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change - Yahoo Finance

ASLNDelisted Stock  USD 0.60  0.03  4.76%   
About 62% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change Yahoo Finance

Read at news.google.com
Google News at Macroaxis
  

Aslan Pharmaceuticals Fundamental Analysis

We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Asset

Net Asset Comparative Analysis

Aslan Pharmaceuticals is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Aslan Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Aslan Pharmaceuticals Related Equities

ANTXAN2 Therapeutics   21.90   
0%
100.0%
GLUEMonte Rosa   13.72   
0%
62.0%
LYRALyra Therapeutics   10.53   
0%
48.0%
IOBTIO Biotech   4.71   
0%
21.0%
CMPXCompass Therapeutics   4.49   
0%
20.0%
CTMXCytomX Therapeutics   3.92   
0%
17.0%
CGEMCullinan Oncology   2.75   
0%
12.0%
ADAGAdagene   1.30   
0%
5.0%
ASMBAssembly Biosciences   1.25   
0%
5.0%
AGIOAgios Pharm   1.24   
0%
5.0%
ACHLAchilles Therapeutics   0.93   
0%
4.0%
ACRVAcrivon Therapeutics,   0.80   
0%
3.0%
ANEBAnebulo Pharmaceuticals   0.70   
0%
3.0%
AVTEAerovate Therapeutics   0.38   
1.0%
0%
IVAInventiva   1.12   
5.0%
0%
GPCRStructure Therapeutics   1.78   
8.0%
0%
ERASErasca   2.05   
9.0%
0%
MLYSMineralys Therapeutics,   2.59   
11.0%
0%
NAMSNewAmsterdam Pharma   4.57   
20.0%
0%
TILInstil Bio   9.39   
42.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Consideration for investing in Aslan Stock

If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Fundamental Analysis
View fundamental data based on most recent published financial statements
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges